Dakappagari Naveen, Zhang Hui, Stephen Laurie, Amaravadi Lakshmi, Khan Masood U
Navigate Biopharma Services, Inc., A Novartis Company, 1890 Rutherford Rd, Carlsbad, CA, USA.
QPS, LLC, 1 Innovation Way, Newark, DE, USA.
Bioanalysis. 2017 Apr;9(8):643-653. doi: 10.4155/bio-2017-0009. Epub 2017 May 15.
With the wide use of biomarkers to enable critical drug-development decisions, there is a growing concern from scientific community on the need for a 'standardized process' for ensuring biomarker specimen stability and hence, a strong desire to share best practices on preserving the integrity of biomarker specimens in clinical trials and the design of studies to evaluate analyte stability. By leveraging representative industry experience, we have attempted to provide an overview of critical aspects of biomarker specimen stability commonly encountered during clinical development, including: planning of clinical sample collection procedures, clinical site training, selection of sample preservation buffers, shipping logistics, fit-for-purpose stability assessments in the analytical laboratory and presentation of case studies covering widely utilized biomarker specimen types.
随着生物标志物在关键药物研发决策中广泛应用,科学界越来越关注确保生物标志物样本稳定性的“标准化流程”的必要性,因此,人们强烈希望分享在临床试验中保存生物标志物样本完整性的最佳实践以及评估分析物稳定性的研究设计。通过借鉴具有代表性的行业经验,我们试图概述临床开发过程中常见的生物标志物样本稳定性的关键方面,包括:临床样本采集程序的规划、临床站点培训、样本保存缓冲液的选择、运输物流、分析实验室中适用的稳定性评估以及涵盖广泛使用的生物标志物样本类型的案例研究展示。